Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pyxis Oncology (PYXS) Research & Development (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Research & Development for 2 consecutive years, with $17.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development changed 0.38% to $17.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $66.0 million, a N/A change, with the full-year FY2024 number at $58.7 million, up 18.47% from a year prior.
  • Research & Development was $17.8 million for Q3 2025 at Pyxis Oncology, up from $17.1 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $17.8 million in Q3 2025 to a low of $13.0 million in Q1 2024.